Delegation of deputies of the State Duma of the Russian Federation and members of the Sverdlovsk Region Government visits the Medsintez Plant to assess pharmaceutical import substitution

On October 10, 2025, a representative delegation visited the Medsintez Plant. Among the visitors, there were members of the State Duma of the Russian Federation, representatives of the Government and Legislative Assembly of the Sverdlovsk Region, the head of the Novouralsk Urban District, and leading regional experts in the field of medical science. The main purpose of the visit was to assess the enterprise's success in import-substituting drug production, become familiar with its brand-new products, and discuss development options of the pharmaceutical industry in the region.

During the visit, the guests toured modern production lines and licensed quality control laboratories where finished dosage forms and high-tech drug substances are produced. A particular highlight was key projects of the plant, which are being implemented under the state import substitution program.

Dmitry Ionin, Acting Deputy Governor of the Sverdlovsk Region, noted: «The Medsintez Plant is a strategically important enterprise for the Russian pharmaceutical industry. It has been included in the National Champions Program.» The status of the National Champion is awarded to Russian rapidly growing businesses in the high-tech industry, which demonstrate cutting-edge developments for import substitution. Dmitry Ionin emphasized that the plant, which was established in Novouralsk 20 years ago, has a strong research infrastructure and qualified personnel.

Vyacheslav Tyumentsev, Mayor of Novouralsk, expressed hope for the enterprise to become another city-forming pillar that provides jobs. «We can see the plant reaching a new level, and despite the challenges, we are ready to provide support for it in all respects, together with our colleagues in the government,» noted Vyacheslav Tyumentsev.

For 25 years, the Medsintez Plant has been contributing to the drug safety of the country by producing vital drugs in accordance with international GMP standards. The enterprise's strategy is focused on the development and production of active pharmaceutical ingredients and high-tech drugs based on modern technology platforms, including organic, biotechnological, and solid-phase peptide synthesis.

The guests were given a tour around the main production facilities, including the production of Primapur, the first Russian human follicle-stimulating hormone drug for infertility treatment. More than 50,000 children have been born thanks to IVF programs using this drug. The delegation was also shown the production of the innovative Russian antiviral drug Triazavirin based on a proprietary molecule that was first synthesized at the Medsintez Plant.

During the visit, representatives of the academic community highly praised the prospects for cooperation with the plant. Developers of the Triazavirin drug—Valery Charushin, Academician of the Russian Academy of Sciences, and Vladimir Rusinov, Corresponding Member of the Russian Academy of Sciences—noted the significant research and production scale of the enterprise, while Olga Kovtun, Academician of the Russian Academy of Sciences, Rector of the Ural State Medical University, and Professor Anatoly Matern expressed confidence in long-term and fruitful collaboration.

In 2025, the plant is implementing a major upgrading project aimed at expanding the production of drugs based on its own peptide and biotechnological substances. It will enable to increase the production volume by 60%, up to 55 million packages per year, and ensure complete independence for the Russian Federation in terms of essential groups of drugs.

According to Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant, the focus is on developing new types of insulin and improved analogues of Semaglutide. «Foreign companies are currently not conducting clinical trials of new insulins in Russia, so this task has fallen entirely on Russian producers. We must address the challenge to cover demands of the country for innovative drugs,» said Alexander Petrov.

The Medsintez Plant is a modern full-cycle biotechnological enterprise located in Novouralsk. The plant actively cooperates with authorities under programs of affordable drug supply. Its strategic goals include the implementation of innovative technologies in line with international standards, expansion into the global market, improvement of an R&D center, development of IT solutions in pharmaceuticals and medical technologies, as well as social support and ongoing personnel development.